Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of eftilagimod alpha in patients with metastatic breast cancer in China

Trial Profile

A clinical trial of eftilagimod alpha in patients with metastatic breast cancer in China

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2018

At a glance

  • Drugs Eftilagimod alpha (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Nov 2018 According to an Immutep media release, first patient dosed in October 2018.
    • 01 Nov 2018 Status changed from planning to recruiting, according to an Immutep media release.
    • 17 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top